Journal of Plastic, Reconstructive & Aesthetic Surgery
Volume 61, Issue 11 , Pages 1275-1283 , November 2008

A review of diagnostic imaging in melanoma

  • A.L. Dancey

      Affiliations

    • Department of Plastic and Reconstructive Surgery, University Hospital of North Staffordshire, City General Hospital, Newcastle Road, Stoke, England, UK
    • Corresponding Author InformationCorresponding author. Departmentt of Plastic and Reconstructive Surgery, University Hospital of North Staffordshire, City General Hospital, Newcastle Road, Stoke-On-Trent ST4 6QG, UK. Tel.: +44 7808078276.
    • ,
  • B.S. Mahon

      Affiliations

    • Department of Radiology, University Hospital Birmingham Foundation Trust, Birmingham, England, UK
    • ,
  • S.S. Rayatt

      Affiliations

    • Department of Plastic and Reconstructive Surgery, University Hospital of North Staffordshire, City General Hospital, Newcastle Road, Stoke, England, UK

Received 13 December 2006 ,Accepted 15 April 2008.

References 

  1. Balch CM, Soong SJ, Murand TM, et al. A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastasis (stage III). J Clin Oncol. 1982;1:126–133
  2. Lee ML, Tomsu K, Von Eschan KB. Duration of survival for disseminated malignant melanoma. Results of a meta-analysis. Melanoma Res. 2000;10:81–92
  3. Patel JK, Didolkar MS, Pickren JW, et al. Metastatic pattern of malignant melanoma: a study of 216 autopsy cases. Am J Surg. 1978;135:807–810
  4. Fleming ID, Cooper JS, Heaston DE, et al. Purposes and principals of staging. AJCC cancer staging manual Philadelphia: Lippincott – Raven; 1997;3–9
  5. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American joint committee on cancer staging system forcutaneous melanoma. J Clin Oncol. 2001;19:3635–3648
  6. Baddeley H. Radiological investigation. A guide to the use of medical imaging in clinical practice. Wiley Medical Publications; 1984;
  7. Terhune MH, Swanson N, Johnson TM. Use of chest radiography in the initial evaluation of patients with localised melanoma. Arch Dermatol. 1998;134:569–572
  8. Hofmann U, Szedlak M, Rittgen W, et al. Primary staging and follow-up in melanoma patients—monocenter evaluation of methods, costs and patient survival. Br J Cancer. 2002;87:151–157
  9. Harland CC, Kale SG, Jackson P, et al. Differentiation of common benign pigmented skin lesions from melanoma by high-resolution ultrasound. Br J Dermatol. 2000;143:281–289
  10. Bessoud B, Lassau N, Koscielny S, et al. High-frequency sonography and color Doppler in the management of pigmented skin lesions. Ultrasound Med Biol. 2003 Jun;29:875–879
  11. Garbe C, Paul A, Kohler-Spath H, et al. Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy. J Clin Oncol. 2003;21:520–529
  12. Machet L, Nemeth-Normand F, Giraudeau B, et al. Is ultrasound lymph node examination superior to clinical examination in melanoma follow-up? A monocentre cohort study of 373 patients. Br J Dermatol. 2005;152:66–70
  13. Saiag P, Bernard M, Beauchet A, et al. Ultrasonography using simple diagnostic criteria vs palpation for the detection of regional lymph node metastases of melanoma. Arch Dermatol. 2005;141:183–189
  14. Kahle B, Hoffend J, Wacker J, et al. Preoperative ultrasonographic identification of the sentinel lymph node in patients with malignant melanoma. Cancer. 2003;97:1947–1954
  15. Deurloo EE, Tanis PJ, Gilhuijs KG, et al. Reduction in the number of sentinel lymph node procedures by preoperative ultrasonography of the axilla in breast cancer. Eur J Cancer. 2003;39:1068–1073
  16. Rossi CR, Mocellin S, Scagnet B, et al. The role of preoperative ultrasound scan in detecting lymph node metastasis before sentinel node biopsy in melanoma patients. J Surg Oncol. 2003;83:80–84
  17. Hocevara M, Brackob M, Pogacnikc A, et al. The role of preoperative ultrasonography in reducing the number of sentinel lymph node procedures in melanoma. Melanoma Res. 2004;14:533–536
  18. Ardizzoni A, Grimaldi A, Repetto L, et al. Stage I–II melanoma: the value of metastatic work-up. Oncology. 1987;44:87–89
  19. Armstrong P. Chest. In:  Armstrong P,  Wastie ML editor. A concise textbook of radiology. London, UK: Arnold; 2001;p. 536–594
  20. Halton KP. Radiological considerations in diagnosis of metastatic melanoma. Mt Sinai J Med. 1992;59:211–216
  21. Heaston DK, Putman CE, Rodan BA, et al. Solitary pulmonary metastasis in high risk melanoma patients: a prospective comparison of conventional and computed tomography. AJR Am J Roentgenol. 1983;141:169–174
  22. Finkelstein SE, Carrasquillo JA, Hoffman JM, et al. A prospective analysis of positron emission tomography and conventional imaging for detection of stage IV metastatic melanoma in patients undergoing metastasectomy. Ann Surg Oncol. 2004;11:731–738
  23. Buzaid AC, Tinoco L, Ross MI, et al. Role of computed tomography in staging of patients with local-regional metastases of melanoma. J Clin Oncol. 1995;13:2104–2108
  24. Jonhson TM, Fader PJ, Chang AE, et al. Computed tomography in staging of patients with melanoma metastatic to regional lymph nodes. Ann Surg Oncol. 1997;4:396–402
  25. Miranda EP, Gertner M, Wall J, et al. Routine imaging of asymptomatic melanoma patients with metastasis to sentinel lymph nodes rarely identifies systemic disease. Arch Surg. 2004;139:831–837
  26. Aloia TA, Gershenwald JE, Andtbacka RH, et al. Utility of computed tomography and magnetic resonance imaging staging before completion lymphadenectomy in patients with sentinel lymph node-positive melanoma. J Clin Oncol. 2006 Jun 20;24:2858–2865
  27. Muller-Horvat C, Radny P, Eigentler TK, et al. Prospective comparison of the impact on treatment decisions of whole-body magnetic resonance imaging and computed tomography in patients with metastatic malignant melanoma. Eur J Cancer. 2006;42:342–350
  28. Lauenstein TC, Goehde SC, Herborn CU, et al. Whole-body MR imaging: evaluation of patients for metastases. Radiology. 2004 Oct;233:139–148
  29. Armstrong P, Haenaur JM, Rezneck RH, et al. Imaging techniques. In:  Armstrong P,  Wastie ML editor. A concise textbook of radiology. London (UK): Arnold; 2001;p. 1–16
  30. Macapinlac HA. The utility of 2-deoxy-2-fluro-D-glucose-positron emission tomography and combined positron emission tomography and computed tomography in lymphoma and melanoma. Mol Imaging Biol. 2004;6:200–207
  31. Hafner J, Schmid MH, Kempf W, et al. Baseline staging in cutaneous malignant melanoma. Br J Dermatol. 2004;150:677–686
  32. Clark PB, Soo V, Kraas J, et al. Futility of fluorodeoxyglucose F18 positron emission tomography in initial evaluation of patients with T2 to T4 melanoma. Arch Surg. 2006;141:284–288
  33. Rinne D, Baum RP, Hor G, et al. Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients. Cancer. 1998;82:1664–1671
  34. Prichard RS, Hill AD, Skehan SJ, et al. Positron emission tomography for staging and management of malignant melanoma. Br J Surg. 2002 Apr;89:389–396
  35. Tyler DS, Onaitis M, Kherani A, et al. Positron emission tomography scanning in malignant melanoma. Cancer. 2000;89:1019–1025
  36. Gulec SA, Faries MB, Lee CC, et al. The role of fluorine-18 deoxyglucose positron emission tomography in the management of patients with metastatic melanoma: impact on surgical decision making. Clin Nucl Med. 2003;28:961–965
  37. Wagner JD. A role for FDG-PET in the surgical management of stage IV melanoma. Ann Surg Oncol. 2004;11:721–722
  38. Acland KM, Healy C, Calonje E, et al. Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of micrometastasis of primary cutaneous malignant melanoma. J Clin Oncol. 2001;19:2674–2678
  39. Wagner JD, Schauwecker D, Davidson D, et al. Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy. J Clin Oncol. 1999;17:1508–1515
  40. Havenga K, Cobben DC, Oyen WJ, et al. Fluorodeoxyglucose-positron emission tomography and sentinel lymph node biopsy in staging primary cutaneous melanoma. Eur J Surg Oncol. 2003;29:662–664
  41. Fink AM, Holle-Robatsch S, Herzog N, et al. Positron emission tomography is not useful in detecting metastasis in the sentinel lymph node in patients with primary malignant melanoma stage I and II. Melanoma Res. 2004;14:141–145
  42. Wagner JD, Schauwecker D, Davidson D, et al. Inefficacy of F–18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma. Cancer. 2005;104:570–579
  43. Franc BL, Mari C, Johnson D, et al. The role of a positron- and high-energy gamma photon probe in intraoperative localization of recurrent melanoma. Clin Nucl Med. December 2005;30:787–791
  44. Pfannenberga C, Aschoff P, Schanza S, Eschmannb SM, Plathowa C, Eigentlerc TK, Garbec C, Brechtela K Vontheind R, Baresb R, Claussena CD, Schlemmera HP, Prospective comparison of 18F-fluorodeoxyglucosepositron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced malignant melanoma. Eur J Cancer 43 (25207) 557–564.
  45. Von Schulthess GK, Steinert HC, Hany TF. Integrated PET/CT: current applications and future directions. Radiology. Feb 2006;238:
  46. Reinhardt MJ, Joe AY, Jaeger U, et al. Diagnostic performance of whole body dual modality 18F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consecutive patients. J Clin Oncol. 2006;24:1178–1187
  47. Iagaru A, Quon A, Johnson D, et al. 2-Deoxy-2-[F-18]fluoro-D-glucose positron emission tomography/computed tomography in the management of melanoma. Mol Imaging Biol. 2006;8:309–314
  48. Schoder H, Larson SM, Yeung HW. PET/CT in oncology: integration into clinical management of lymphoma, melanoma, and gastrointestinal malignancies. J Nucl Med. 2004;45:
  49. Blodgett TM, Meltzer CC, Townsend DW. PET/CT: form and function. Radiology. 2007 Feb;242:360–385
  50. Strobel K, Dummer R, Husarik DB, et al. Steinert HC High-risk melanoma: accuracy of FDG PET/CT with added CT morphologic information for detection of metastases. Radiology. 2007 Aug;244:566–574
  51. Au FC, Marier WP, Malmud LS, et al. Preoperative nuclear scans in patients with melanoma. Cancer. 1984;59:2095–2097
  52. Uren FR, Howman-Giles R, Chung D, et al. Nuclear Medicine Aspects of melanoma and breast lymphatic mapping. Semin Oncol. 2004;31:338–348
  53. Gershenwald JE, Thompson W, Mansfield PF, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol. 1999;17:976–986
  54. Hettiaratchy SP, Kang N, O'Toole G, et al. Sentinel lymph node biopsy in malignant melanoma: a series of 100 consecutive patients. Br J Plast Surg. 2000 Oct;53:559–562
  55. Morton DL, Cochran AJ, Thompson JF, et al. Multicenter selective lymphadenectomy trial group. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg. 2005 Sep;242:302–311
  56. Essner R, Scheri R, Kavanagh M, et al. Surgical management of the groin lymph nodes in melanoma in the era of sentinel lymph node dissection. Arch Surg. 2006 Sep;141:877–882
  57. Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006 Sep 28;355:1307–1317
  58. Reinus WR. American radiology and outsourcing. Radiology. 2007 Mar;242:654–657
  59. Hollingworth W. Radiology cost and outcomes studies: standard practice and emerging methods. AJR Am J Roentgenol. 2005 Oct;185:833–839
  60. http://www.dh.gov.uk/refcosts
  61. http://www.cms.hhs.gov/PFSlookup/02_PFSSearch.asp(accessed 04.11.07)
  62. Hofmann U, Szedlak M, Rittgen W, et al. Primary staging and follow-up in melanoma patients–monocenter evaluation of methods, costs and patient survival. Br J Cancer. 2002 Jul 15;87:151–157
  63. Newton Bishop JA, Corrie PG, Evans J, et al. UK guidelines for the management of cutaneous melanoma. Br J Plast Surg. 2002;55:46–54
  64. Sober AJ, Chuang TY, Duvic M, et al. Guideline of care for primary cutaneous melanoma. J Am Acad Dermatol. 2001;45:579–586
  65. Poo-Hwu W-J, Ariyan S, Lamb L, et al. Follow-up recommendations for patients with American Joint Committee on Cancer stages I–III malignant melanoma. Cancer. 1999;86:2252–2258

PII: S1748-6815(08)00615-3

doi: 10.1016/j.bjps.2008.04.034

Journal of Plastic, Reconstructive & Aesthetic Surgery
Volume 61, Issue 11 , Pages 1275-1283 , November 2008

Article Tools

* Image Usage & Resolution